このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

これは、多発性硬化症 (MS) の参加者におけるオクレリズマブの安全性と有効性を調査するための Roche P 試験の拡張研究です。

2026年8月28日 更新者:Hoffmann-La Roche

F.ホフマン・ラ・ロシュがスポンサーとなったオクレリズマブの第IIIb/IV相臨床試験に以前に登録された多発性硬化症患者におけるオクレリズマブの有効性と安全性を評価するための、単一群の非盲検多施設拡大試験

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).

調査の概要

状態

完了

介入・治療

詳細な説明

This is a single arm, open label, multicenter extension study in participants who completed treatment period with ocrelizumab in the Roche P-trials. Participants will receive treatment with ocrelizumab as single 600 mg infusions every 24 weeks for two years.

研究の種類

介入

入学 (実際)

1055

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Dublin、アイルランド
        • St Vincents University Hospital
      • Buenos Aires、アルゼンチン、C1437JCP
        • Hospital Churruca Visca
      • Ciudad Autonoma Buenos Aires、アルゼンチン、C1061ABD
        • Centro de Especialidades Neurológicas y Rehabilitación - CENyR
      • Rosario、アルゼンチン、2000
        • Fundacion Rosarina de Neurorehabilitacion
      • Exeter、イギリス、EX2 5DW
        • Royal Devon and Exeter Hospital (Wonford)
      • Glasgow、イギリス、G51 4TF
        • Queen Elizabeth University Hospital
      • Inverness、イギリス、IV2 3UV
        • Raigmore Hospital
      • Leeds、イギリス、LS9 7AU
        • Leeds Teaching Hospitals NHS Trust
      • London、イギリス、SW17 0QT
        • St George's Hospital
      • London、イギリス、W6 8RF
        • Charing Cross Hospital
      • London、イギリス、SE5 9RS
        • Kings College Hospital
      • London、イギリス、E1 1BB
        • The Royal London Hospital
      • London、イギリス、NW3 2QS
        • Royal Free Hospital
      • London、イギリス、WC1 3BG
        • National Hospital for Neurology and Neurosurgery,
      • Newcastle upon Tyne、イギリス、NE1 4LP
        • Royal Victoria Infirmary
      • Salford、イギリス、M6 8HD
        • Salford Royal NHS Foundation Trust
      • Sheffield、イギリス、S10 2JF
        • Royal Hallamshire Hospita
      • Swansea、イギリス、SA6 6NL
        • Morriston Hospital
      • Truro、イギリス、TR1 3LQ
        • Royal Cornwall Hospital
    • Abruzzo
      • Chieti、Abruzzo、イタリア、66013
        • Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla
      • L’Aquila、Abruzzo、イタリア、67100
        • Ospedale San Salvatore
    • Apulia
      • San Giovanni Rotondo、Apulia、イタリア、71013
        • IRCCS Ospedale Casa Sollievo Della Sofferenza
    • Campania
      • Naples、Campania、イタリア、80131
        • A. O. U. Federico II
      • Naples、Campania、イタリア、80131
        • Università degli Studi della Campania Luigi Vanvitelli
    • Emilia-Romagna
      • Bologna、Emilia-Romagna、イタリア、40139
        • Ospedale Bellaria
    • Lazio
      • Rome、Lazio、イタリア、00168
        • Policlinico Universitario A. Gemelli
      • Rome、Lazio、イタリア、00189
        • Azienda Ospedaliera Sant'Andrea
      • Rome、Lazio、イタリア、00152
        • Ospedale S.Camillo Forlanini
      • Rome、Lazio、イタリア、00133
        • Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
    • Liguria
      • Genoa、Liguria、イタリア、16132
        • Irccs A.O.U.San Martino Ist
    • Lombardy
      • Bergamo、Lombardy、イタリア、24127
        • ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
      • Gallarate、Lombardy、イタリア、21013
        • Ospedale S.Antonio Abate
      • Milan、Lombardy、イタリア、20132
        • IRCCS Ospedale San Raffaele
      • Milan、Lombardy、イタリア、20133
        • Fond. Istituto Neurologico C.Besta
      • Milan、Lombardy、イタリア、20122
        • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
      • Montichiari、Lombardy、イタリア、25018
        • Ospedale Civile di Montichiari
      • Pavia、Lombardy、イタリア、27100
        • IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla
    • Molise
      • Pozzilli、Molise、イタリア、86077
        • IRCCS Istituto Neurologico Neuromed
    • Sardinia
      • Cagliari、Sardinia、イタリア、09126
        • Ospedale Binaghi
    • Sicily
      • Catania、Sicily、イタリア、95123
        • AOU Policlinico V. Emanuele - P.O G. Rodolico
      • Cefalù、Sicily、イタリア、90015
        • Fondazione Istituto S. Raffaele - Giglio
      • Palermo、Sicily、イタリア、90129
        • AOU Policlinico Giaccone
      • Palermo、Sicily、イタリア、90146
        • AO Ospedali Riuniti Villa Sofia-Cervello
    • The Marches
      • Ancona、The Marches、イタリア、60100
        • AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi
    • Tuscany
      • Florence、Tuscany、イタリア、50134
        • AOUC Azienda Ospedaliero-Universitaria Careggi
      • Florence、Tuscany、イタリア、50134
        • AOU Careggi
      • Siena、Tuscany、イタリア、53100
        • AOU Senese - Presidio Ospedaliero Le Scotte
    • Umbria
      • Perugia、Umbria、イタリア、06156
        • AO di Perugia - Ospedale S. Maria della Misericordia
    • Veneto
      • Padova、Veneto、イタリア、35128
        • Azienda Ospedaliera di Padova
      • Verona、Veneto、イタリア、37134
        • Policlinico G.B. Rossi
      • Tallinn、エストニア、10138
        • East Tallinn Central Hospital
      • Tallinn、エストニア、10617
        • West Tallinn Central Hospital
      • Tartu、エストニア、51014
        • Tartu University Hospital
      • 's-Hertogenbosch、オランダ、5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Amsterdam、オランダ、1081 HV
        • Amsterdam UMC Location VUMC
      • Breda、オランダ、4819 EV
        • Amphia Ziekenhuis
      • Gouda、オランダ、2803 HH
        • Groene Hart Ziekenhuis
      • NL -rotterdam、オランダ、3079 DZ
        • Maasstadziekenhuis
      • Sittard-Geleen、オランダ、6162 BG
        • Zuyderland Medisch Centrum - Sittard Geleen
      • Tilburg、オランダ、5022 GC
        • Elisabeth-TweeSteden Ziekenhuis
    • British Columbia
      • Vancouver、British Columbia、カナダ、V6T 1Z4
        • University of British Columbia
    • Ontario
      • London、Ontario、カナダ、N6A 5A5
        • London Health Sciences Centre Uni Campus
      • Ottawa、Ontario、カナダ、K1H 8L6
        • The Ottawa Hospital - General Campus
      • Toronto、Ontario、カナダ、M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Gatineau、Quebec、カナダ、J8Y 1W2
        • Clinique NeuroOutaouais
      • Greenfield Park、Quebec、カナダ、J4V 2J2
        • Recherche Sepmus Inc.
      • Montreal、Quebec、カナダ、H3A 2B4
        • Montreal Neurological Institute and Hospital
      • Kuwait City、クウェート、10002
        • Ibn Sina Hospital
      • Zagreb、クロアチア、10000
        • Clinical Hospital Centre Zagreb
      • Gothenburg、スウェーデン、413 45
        • Sahlgrenska Sjukhuset
      • Karlstad、スウェーデン、65185
        • Centralsjukhuset
      • Stockholm、スウェーデン、113 41
        • Centrum för Neurologi
      • Barcelona、スペイン、08035
        • Hospital Vall d'Hebron
      • Cadiz、スペイン、11009
        • Hospital Puerta del Mar
      • Girona、スペイン、17007
        • Hospital Universitari de Girona Dr. Josep Trueta
      • Madrid、スペイン、28041
        • Hospital Universitario 12 de Octubre
      • Madrid、スペイン、28046
        • Hospital Universitario La Paz
      • Madrid、スペイン、28006
        • Universitario de La Princesa
      • Madrid、スペイン、28040
        • Hospital Universitario Clínico San Carlos
      • Murcia、スペイン
        • Hospital Universitario Virgen de Arrixaca
      • Seville、スペイン、41009
        • Hospital Universitario Virgen Macarena
      • Valencia、スペイン、46010
        • Hospital Clinico Universitario de Valencia
      • Valencia、スペイン、46026
        • Hospital Universitario la Fe
    • Barcelona
      • L'Hospitalet de Llobregat、Barcelona、スペイン、08907
        • Hospital Universitari de Bellvitge
    • Castellon
      • Castellon、Castellon、スペイン、12004
        • Hospital General de Castellon
    • LA Coruna
      • A Coruña、LA Coruna、スペイン、15006
        • Complejo Hospitalario Universitario A Coruña (CHUAC)
    • Lerida
      • Lleida、Lerida、スペイン、25198
        • Hospital Universitari Arnau de Vilanova de Lleida
    • Madrid
      • Pozuelo de Alarcón、Madrid、スペイン、28223
        • Hospital Quiron de Madrid
    • Pontevedra
      • Vigo、Pontevedra、スペイン、36312
        • Complejo Hospitalario Universitario de Vigo - Xeral Cies
    • Principality of Asturias
      • Oviedo、Principality of Asturias、スペイン
        • Hospital Universitario Central de Asturias
      • Bratislava、スロバキア、813 69
        • Univerzitna nemocnica Bratislava
      • Bratislava、スロバキア、826 06
        • Univerzitna nemocnica Bratislava Nemocnica Ruzinov
      • Trnava、スロバキア、917 75
        • Fakultna nemocnica Trnava
      • Ljubljana、スロベニア、1000
        • University Medical Centre
      • Maribor、スロベニア、2000
        • University Medical Centre Maribor
      • Brno、チェコ、656 91
        • Fakultni nemocnice u sv. Anny
      • Jihlava、チェコ、58633
        • Nemocnice Jihlava
      • Prague、チェコ、12808
        • VFN Praha Poliklinika Rs Centrum - Budova A
      • Prague、チェコ、150 06
        • Fakultni nemocnice v Motole
      • Aalborg、デンマーク、9000
        • Aalborg Universitetshospital
      • Aarhus N、デンマーク、8200
        • Aarhus Universitetshospital
      • Glostrup Municipality、デンマーク、2600
        • Rigshospitalet Glostrup
      • Odense C、デンマーク、5000
        • Odense Universitetshospital, Neurologisk Afdeling N
      • Sønderborg、デンマーク、6400
        • Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
      • Ankara、トルコ(Türkiye)、06500
        • Gazi University Medical Faculty
      • Ankara、トルコ(Türkiye)、06100
        • Hacettepe University Medical Faculty
      • Hatay、トルコ(Türkiye)、31001
        • Mustafa Kemal Ataturk UTF
      • Istanbul、トルコ(Türkiye)、34098
        • Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi
      • Istanbul、トルコ(Türkiye)、34093
        • Istanbul University Istanbul School of Medicine
      • Konya、トルコ(Türkiye)、42131
        • Selcuk University Medical Faculty
      • Samsun、トルコ(Türkiye)、55139
        • Ondokuz Mayis University School of Medicine
      • Trabzon、トルコ(Türkiye)、61080
        • Karadeniz Tecnical Uni. Med. Fac.
      • Bergen、ノルウェー、5021
        • Haukeland universitetssykehus
      • Drammen、ノルウェー、3004
        • Sykehuset Buskerud HF
      • Stavanger、ノルウェー、4011
        • Stavanger Universitetssykehus, Helse Stavanger HF
      • Budapest、ハンガリー、1204
        • Budapesti Jahn Ferenc Dél-pesti Kórház és Rendel?intézet
      • Esztergom、ハンガリー、2500
        • VALEOMED Diagnosztikai Központ
      • Turku、フィンランド、20520
        • Mehiläinen Neo Turku
      • Besançon、フランス、25030
        • CHU de Besancon Hopital Jean Minjoz
      • Bordeaux、フランス、33076
        • Groupe Hospitalier Pellegrin
      • Bron、フランス、69677
        • Hopital neurologique Pierre Wertheimer - CHU Lyon
      • Clermont-Ferrand、フランス、63003
        • Hopital Gabriel Montpied CHU de Clermont-Ferrand
      • Gonesse、フランス、95503
        • CH de Gonesse
      • La Tronche、フランス、38700
        • CHU de Grenoble
      • Lille、フランス、59037
        • Hopital Roger Salengro Service de Neurologie
      • Marseille、フランス、13005
        • CHU de la Timone - Hopital d Adultes
      • Montpellier、フランス、34295
        • Hopital Gui de Chauliac
      • Nancy、フランス、54035
        • Hopital Central - CHU de Nancy
      • Nantes、フランス、44805
        • Hôpital Guillaume et René Laënnec
      • Nice、フランス、06002
        • Hôpital Pasteur
      • Nîmes、フランス、30900
        • CHU de Nîmes Hopital Caremeau
      • Paris、フランス、75651
        • Groupe Hospitalier Pitié- Salpétrière
      • Poissy、フランス、78300
        • Hôpital de Poissy
      • Rouen、フランス、76031
        • CHU de Rouen Hopital
      • Strasbourg、フランス、67098
        • Höpital Hautepierre
      • Toulon、フランス、83041
        • HIA de Toulon hôpital militaire
    • Paraná
      • Curitiba、Paraná、ブラジル、81210-310
        • Instituto de Neurologia de Curitiba
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、ブラジル、90610-000
        • Hospital Sao Lucas - PUCRS
    • São Paulo
      • São Paulo、São Paulo、ブラジル、05403-900
        • Hospital das Clinicas - FMUSP
      • Sofia、ブルガリア、1113
        • Shat Np Sveti Naum
      • Sofia、ブルガリア、1309
        • Multiprofile Hosp. for Active Treatment
      • Bruges、ベルギー、8000
        • AZ Sint Jan
      • Edegem、ベルギー、2650
        • UZ Antwerpen
      • La Louvière、ベルギー、7100
        • CHU Tivoli
      • Liège、ベルギー、4000
        • CHU de Liège (Sart Tilman)
      • Overpelt、ベルギー、3900
        • Revalidatie en MS Centrum
      • Braga、ポルトガル、4710-243
        • Hospital de Braga
      • Coimbra、ポルトガル、3000-075
        • HUC
      • Loures、ポルトガル、2674-514
        • Hospital Beatriz Angelo
      • Porto、ポルトガル、4099-001
        • Hospital Geral de Santo Antonio
      • Bydgoszcz、ポーランド、85-796
        • Neurocentrum Bydgoszcz sp. z o.o
      • Gdansk、ポーランド、80-803
        • COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika
      • Katowice、ポーランド、40-568
        • Care Clinic
      • Krakow、ポーランド、31-637
        • Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o.
      • Lodz、ポーランド、90-324
        • Centrum Neurologii Krzysztof Selmaj
      • Lublin、ポーランド、20-410
        • Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak.
      • Warsaw、ポーランド、02-097
        • Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
      • Warsaw、ポーランド、02-957
        • Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
      • Mexico City、メキシコ、14050
        • Unidad de investigacion en salud (UIS)
    • Mexico CITY (federal District)
      • Mexico City、Mexico CITY (federal District)、メキシコ、06726
        • Hospital General de México
    • Sinaloa
      • Culiacán、Sinaloa、メキシコ、80020
        • Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Signed Informed Consent Form
  • Able to comply with the study protocol, in the investigator's judgment
  • Completed the treatment period of Roche sponsored ocrelizumab P-trials

Exclusion Criteria:

  • Hypersensitivity to ocrelizumab or to any of its excipients.
  • Participantss in a severely immunocompromised state until the condition resolves.
  • Evidence of any adverse event potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation.
  • Existence of a contra-indication as per SmPC
  • Prohibited concomitant medication as specified in protocol
  • Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug in the parent study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Ocrelizumab

Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.

Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline Expanded Disability Status Scale (EDSS) score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using Kaplan-Meier(K-M) method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to Onset of CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to Onset of CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to Onset of CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had Confirmed Disability Improvement (CDI) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated &scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDI Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated &scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at two scheduled visits at least 48 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at two scheduled visits at least 48 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had Improved, Stable or Worsened Disability Compared With CASTING Baseline in EDSS Category at LIBERTO Week 96
時間枠:At LIBERTO Week 96

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Participants were considered stable when the change from baseline in score was between -0.5 and +0.5, worsened when the change was > 0.5, and improved when the change in score was < -0.5. Percentages are rounded off.

At LIBERTO Week 96
Percentage of Participants Who Had Stable or Worsened Disability Compared With ENSEMBLE Baseline in EDSS Category at LIBERTO Week 96
時間枠:At LIBERTO Week 96

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Participants were considered stable when the change from baseline in score was between -0.5 and +0.5 and worsened when the change was > 0.5. Percentages are rounded off.

At LIBERTO Week 96
Change From CASTING Baseline in EDSS Score to LIBERTO Week 96
時間枠:CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM).

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in EDSS Score to LIBERTO Week 96
時間枠:ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Estimates are from analysis based on MMRM.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 25-foot Walk Test (T25FWT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 24-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 48-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 9 Hole Peg Test (9HPT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 24-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 48-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 24-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 48-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 24-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 48-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

二次結果の測定

結果測定
メジャーの説明
時間枠
Time to First Protocol-Defined Event of Disease Activity
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disease activity was defined as at least one the following events: protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to MS. Symptoms must persist for > 24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications), and immediately be preceded by neurological stability for at least 30 days.); 24 weeks CDP based on increases in EDSS; a new T1 Gadolinium (Gd)-enhanced lesion; or a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI). The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to First Relapse
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

A protocol-defined MS relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/ FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. or ≥1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Annualized Protocol-Defined Relapse Rate
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

ARR=total number of relapses for all participants divided by the total years of drug exposure (from first day of infusion in parent study until LIBERTO week 96). Protocol-defined MS relapse=occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours & not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on 1 of the FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual or ≥1 point on 2 or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. EDSS scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Adjusted ARR is reported.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Relapse Free Participants
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

A protocol-defined MS relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/ FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. or ≥1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. The EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Protocol-Defined Event of Disease Activity (NEDA) for CASTING Rollover Cohort
時間枠:From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Percentage of participants with NEDA where disease activity = at least 1 of the following events: protocol defined relapse (PDR); 24 weeks CDP based on increases in EDSS while on treatment with ocrelizumab; a T1 Gd-enhanced lesion on MRI; or a new and/or enlarging T2 hyperintense lesion on MRI. PRD as defined in outcome measure 22. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS was 5.5 or less, and ≥ 0.5 when BS was above 5.5. Participants with EDSS of 0, progression was defined aschange of ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants With NEDA for ENSEMBLE Cohort
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEDA where disease activity = at least 1 of the following events: protocol defined relapse (PDR); 24 weeks CDP based on increases in EDSS while on treatment with ocrelizumab; a T1 Gd-enhanced lesion on MRI; or a new and/or enlarging T2 hyperintense lesion on MRI. PRD as defined in outcome measure 22. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS was 5.5 or less, and ≥ 0.5 when BS was above 5.5. Participants with EDSS of 0, progression was defined aschange of ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death).

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Evidence of Progression (NEP) From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEP =no progression sustained for at least 24 weeks on: CDP; 20% increase in timed T25FWT; 20% increase in timed 9HPT yearly & over the course of the study. CDP= increase of ≥ 1.0 point from the baseline EDSS score when BS= 5.5 or less, & ≥ 0.5 when the BS= above 5.5. For participants with an EDSS of 0, progression=change ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. The EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). In T25FWT test participants walked to a 25 foot course as quickly & safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. In T25FWT & 9-HPT the longer it took complete test= higher scores, indicating deterioration.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Evidence of Progression Sustained for at Least 24 Weeks and Disease Activity (NEPAD) From ENSEMBLE Baseline ENSEMBLE to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEPAD=no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse & no enlarging or new T2/ T1 Gd-enhancing lesion yearly & over the course of treatment. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS= 5.5 or less, & ≥ 0.5 when BS= above 5.5. Participants with EDSS of 0, progression=change ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death). In T25FWT test participants walked 25-foot course as quickly & safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. In T25FWT & 9-HPT the longer it took to complete test= higher scores, indicating deterioration.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From Baseline in Symbol Digit Modalities Test (SDMT) Score for CASTING Rollover Cohort
時間枠:CASTING Baseline to LIBERTO Week 96 (up to 4 years)

SDMT test consists of a sequence of 110 symbols to be displayed in a maximum 90 seconds and a reference key legend (3 versions are available) with 9 symbols in a given order and their respective matching digits from 1 to 9. This test measures the speed (number of correct paired responses) to pair abstract symbols with specific digits in 90 seconds time. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and minimum of 0. Higher scores indicate improvement.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to 8-point Improvement Change in the SDMT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
時間枠:From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

SDMT test consists of a sequence of 110 symbols to be displayed in a maximum 90 seconds and a reference key legend (3 versions are available) with 9 symbols in a given order and their respective matching digits from 1 to 9. This test measures the speed (number of correct paired responses) to pair abstract symbols with specific digits in 90 seconds. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and a minimum of 0. Higher scores indicate improvement.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Rate of Gadolinium-enhancing Lesions on T1Gd+ Lesions as Detected by Brain MRI
時間枠:From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of T1 Gd-enhanced lesions for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Rate of New or Enlarging T2 Lesions as Detected by Brain MRI
時間枠:From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of new and/or enlarging T2 lesions for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Change in Total T1 Hypointense Lesion Volume Detected by Brain MRI
時間枠:At LIBERTO Week 96

Estimates are from analysis based on mixed-effect model of repeated measures (MMRM)

At LIBERTO Week 96
Rate of Fluid-Attenuated Inversion Recovery (FLAIR) Late Enhancing Lesions With Leakage as Detected by Brain MRI Over Time
時間枠:From LIBERTO Week 24 to LIBERTO Week 96; From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of FLAIR for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From LIBERTO Week 24 to LIBERTO Week 96; From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Percentage Change in Brain Volume as Detected by Brain MRI Over Time
時間枠:From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Percentage Change in White Matter Volume as Detected by Brain MRI Over Time
時間枠:From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Percentage Change in Cortical Grey Matter Volume as Detected by Brain MRI Over Time
時間枠:From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE Week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Time to Treatment Discontinuation
時間枠:From LIBERTO Baseline to LIBERTO Week 96 (up to 6 years)
From LIBERTO Baseline to LIBERTO Week 96 (up to 6 years)
Mean Work Productivity and Activity Impairment (WPAI) Score for CASTING Rollover Cohort
時間枠:CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The WPAI employment status questionnaire is a PRO consisting of 6 items that assess working status, specifically the impact of MS on absenteeism, presentism, work productivity loss and activity impairment over the past 7 days. Four sub scores are calculated and presented as a percentage. Absenteeism = percent work time missed due to problem; Presenteeism = percent impairment while working due to problem; Work productivity= percent overall work impairment due to problem; Activity Impairment = percent activity Impairment due to problem). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Mean WPAI Score for ENSEMBLE Rollover Cohort
時間枠:ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The WPAI employment status questionnaire is a PRO consisting of 6 items that assess working status, specifically the impact of MS on absenteeism, presentism, work productivity loss and activity impairment over the past 7 days. Four sub scores are calculated and presented as a percentage. Absenteeism = percent work time missed due to problem; Presenteeism = percent impairment while working due to problem; Work productivity= percent overall work impairment due to problem; Activity Impairment = percent activity Impairment due to problem). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in SymptoMScreen Score to LIBERTO Week 96
時間枠:CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The SymptoMScreen comprises 12 distinct domains representing common MS symptoms: mobility, dexterity, vision, fatigue, cognition, bladder function, sensation, dizziness, spasticity, body pain, depression, and anxiety. Limitations associated with each symptom are rated on a 7-point Likert scale ranging from 0 ("not affected at all") to 6 ("total limitation; I am unable to perform most daily activities"). Domain scores are summed to generate a total score ranging from 0 to 72, with higher scores indicating greater symptom-related limitations.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in SymptoMScreen Score to LIBERTO Week 96
時間枠:ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The SymptoMScreen comprises 12 distinct domains representing common MS symptoms: mobility, dexterity, vision, fatigue, cognition, bladder function, sensation, dizziness, spasticity, body pain, depression, and anxiety. Limitations associated with each symptom are rated on a 7-point Likert scale ranging from 0 ("not affected at all") to 6 ("total limitation; I am unable to perform most daily activities"). Domain scores are summed to generate a total score ranging from 0 to 72, with higher scores indicating greater symptom-related limitations.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in Multiple Sclerosis Impact Scale (MSIS-29), Physical Scale Score to LIBERTO Week 96
時間枠:CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The MSIS-29 version 2 (MSIS-29v2) is a 29-item patient-reported outcome (PRO) measure designed to assess the physical and psychological impact of MS. The Physical Scale consists of 20 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw physical impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better health-related quality of life (HRQoL).

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in MSIS-29, Physical Scale Score to LIBERTO Week 96
時間枠:ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Physical Scale consists of 20 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw physical impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in MSIS-29, Psychological Scale Score to LIBERTO Week 96
時間枠:CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Psychological Scale consists of 9 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in MSIS-29, Psychological Scale Score to LIBERTO Week 96
時間枠:ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Psychological Scale consists of 9 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Number of Participants With Adverse Events (AEs)
時間枠:From CASTING Baseline to LIBERTO SFU (up to 4.9 years); From ENSEMBLE Baseline to LIBERTO SFU (up to 6.9 years)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

From CASTING Baseline to LIBERTO SFU (up to 4.9 years); From ENSEMBLE Baseline to LIBERTO SFU (up to 6.9 years)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Trials、Hoffmann-La Roche

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年7月12日

一次修了 (実際)

2025年7月17日

研究の完了 (実際)

2025年7月17日

試験登録日

最初に提出

2018年6月25日

QC基準を満たした最初の提出物

2018年7月23日

最初の投稿 (実際)

2018年7月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年8月28日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • MN39158
  • 2017 (米国 NIH グラント/契約)
  • 2017-004886-29 (EudraCT番号)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する